Press Release

Disclosure of transactions with related parties pursuant to Section 111c

12 May 2026

Jena, Germany | May 12, 2026 | Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (the "Company") hereby discloses, pursuant to Section 111c (2) of the German Stock Corporation Act (AktG), the transactions described below with Carl Zeiss AG, Oberkochen, as a related party within the meaning of Section 111a (1) Sentence 2 of the AktG.

  • On 12 May 2026, the Management Board of the Company resolved to enter into a lease agreement with Carl Zeiss AG for the future headquarters at the Jena site ("Jena high-tech site") based on the following key terms and conditions: The base rent amounts to €8.8m per year and shall be paid by the Company starting from the 2027/28 fiscal year. Including the existing production facilities that will continue to be used, the Company's total lease expenses towards Carl Zeiss AG will increase from approximately EUR 2 million in fiscal year 2024/25 to approximately EUR 10 million per year from fiscal year 2027/28. On this basis, the lease agreement is now to be finalized and concluded shortly thereafter.
  • Furthermore, on 12 May 2026, Carl Zeiss Meditec AG and Carl Zeiss AG reached an agreement regarding an increase in costs for passing on additional costs for services provided within the Group. These include, in particular, IT, HR and other shared services, for which the ZEISS Group has incurred considerable additional expenses in recent years due to wage inflation and increased infrastructure costs. The total annual expense charged to the Company for these services will increase in three steps by a total of approximately EUR 30 million starting in the current 2025/26 fiscal year and continuing through the 2028/29 fiscal year.

The aforementioned agreements constitute transactions with related parties within the meaning of section 111a et seq. of the German Stock Corporation Act (AktG). Carl Zeiss AG, based in Oberkochen, as the parent company, holds the majority of voting rights in Carl Zeiss Meditec AG and therefore constitutes a related party within the meaning of Section 111a (1) Sentence 2 of the German Stock Corporation Act (AktG).

The Supervisory Board of Carl Zeiss Meditec AG approved the aforementioned transactions in accordance with Section 111b (1) German Stock Corporation Act (AktG) on 8 May 2026 and authorized the Management Board to conclude the corresponding transactions.

Jena, 12 May 2026
Carl Zeiss Meditec AG
The Management Board

Portrait of Sebastian Frericks
Press & Investor Relations Contact Sebastian Frericks

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumables. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,227.6m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float, 2 percent are held as treasury shares, the remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med


Share this page